Literature DB >> 27587241

[The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition)].

.   

Abstract

Entities:  

Year:  2016        PMID： 27587241     DOI： 10.3760/cma.j.issn.0253-2727.2016.08.001

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  17 in total

1.  Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.

Authors:  Li-Feng Chen; Guo-Lin Yuan; Zhao-Dong Zhong; Ping Zou; Deng-Ju Li; Yin Bao; Hong-Bo Ren; Li Meng; Wei-Ming Li
Journal:  Curr Med Sci       Date:  2018-12-07

2.  [Comparison of nilotinib vs imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase].

Authors:  L Yu; Y Z Qin; Y Y Lai; H X Shi; X J Huang; Y Hou; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

3.  [Efficacy, safety and health-related life quality of chronic myeloid leukemia during the chronic period switching from branded Gleevec or Tasigna to generic imatinib].

Authors:  T Zhao; L Yu; Y Z Qin; X J Huang; Y Hou; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-09-14

4.  [Effect of nilotinib on pregnancy outcome in female patients with chronic myeloid leukemia].

Authors:  H F Zhao; Y P Song; Z Li; J Zhou; F K Yu; R R Gui; Y L Zu; X D Wei; Yanli Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

5.  Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Authors:  Na Li; Bin Zheng; Hong-Fu Cai; Jing Yang; Xiao-Feng Luo; Li-Zhu Weng; Feng-Mei Zhan; Mao-Bai Liu
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

6.  Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors.

Authors:  Zhihe Liu; Hongqiong Fan; Yuying Li; Chunshui Liu
Journal:  Onco Targets Ther       Date:  2017-07-17       Impact factor: 4.147

7.  An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.

Authors:  Bin Wu; Maobai Liu; Te Li; Houwen Lin; Hua Zhong
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

8.  [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14

Review 9.  [Myelodysplastic syndrome with Philadelphia negative+8 clonal chromosomal abnormalities after tyrosine kinase inhibitors therapy for chronic myeloid leukemia: a case report and literature].

Authors:  Y Liu; Y Y Zhang; W Han; X H Zhang; X J Huang; L P Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14

10.  [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].

Authors:  T Yuan; Y Y Lai; Y Z Qin; H X Shi; X J Huang; Y Hou; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.